1. Home
  2. BANL vs MBRX Comparison

BANL vs MBRX Comparison

Compare BANL & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

N/A

Current Price

$3.07

Market Cap

6.1M

Sector

Energy

ML Signal

N/A

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

N/A

Current Price

$7.83

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BANL
MBRX
Founded
2015
2015
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
6.4M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
BANL
MBRX
Price
$3.07
$7.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $240.00
AVG Volume (30 Days)
15.5K
★ 144.8K
Earning Date
08-18-2026
11-24-2026
Dividend Yield
★ 3.42%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.16
52 Week High
$16.40
$11.47

Technical Indicators

Market Signals
Indicator
BANL
MBRX
Relative Strength Index (RSI) 40.76 67.68
Support Level $2.77 $2.12
Resistance Level $5.18 $10.24
Average True Range (ATR) 0.35 0.91
MACD 0.08 -0.24
Stochastic Oscillator 11.59 24.43

Price Performance

Historical Comparison
BANL
MBRX

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: